

AMICUS SIGNS NOVEL PAIN COMBO *MAXIGESIC*™ FOR BALTICS, CENTRAL EUROPE AND WEST BALKANS

PRESS RELEASE NO. 16: AMICUS AG and AFT Pharmaceuticals Ltd. of Auckland, New Zealand have concluded a licensing agreement for AFT's novel painkiller Maxigesic™ in 3 regions: the Baltics (Latvia, Estonia and Lithuania); Central Europe (Czech Republic, Hungary, Bulgaria, Romania and Slovakia); and most of the West Balkans (Croatia, Slovenia, Serbia, Montenegro, Bosnia and Macedonia).

Baar, Switzerland July 20th, 2017: AFT Pharmaceuticals and Amicus A.G. signed a long-term licensing agreement yesterday which provides for Amicus to commercialize AFT's medicine *Maxigesic* across fourteen countries of Central and Eastern Europe.

Maxigesic consists of a patented, fixed ratio of ibuprofen for anti-inflammation management and paracetamol (also called acetaminophen) for opioid-sparing pain management. *Maxigesic* products covered by this new agreement will include tablet, sachet, oral liquid, fast-dissolve and dry powder sticks.

"This agreement with AFT marks another breakthrough for Amicus as a company," commented Amicus Board Member and co-Founder, Petr Nemeč. "The AFT relationship covers virtually all of Amicus' existing territory as well as several new countries that we intended to enter – meaning that *Maxigesic* will spearhead Amicus' entry into new territories such as Hungary, Bulgaria and Czech Republic, as well as build on our strong OTC presence in existing Amicus countries."

Amicus CEO Jean-Michel Lespinasse commented that "Amicus was honored to be selected by AFT as its long-term licensing partner across a large central European territory. We are excited to be able to roll-out a novel pain reliever with both an efficacy and safety claim," Lespinasse continued, pointing out that "*Maxigesic* marks a strategic evolution for Amicus, whereby we are licensing, long-term, a novel combination and building real value for the company through ownership of the trademark....We look forward to successful launches in early 2018 and to build *Maxigesic* into a major brand in the territory."

Under the agreement, Amicus subsidiaries or partners in each of the countries will commercialize and promote *Maxigesic*, providing a full panoply of services including A&P, media buy, distribution, access, regulatory, medical affairs and pharmacovigilance.

About AFT

AFT was founded in 1997 and is an Auckland, New Zealand, based pharmaceuticals company operating in Australia, New Zealand and the Pacific Islands. AFT is listed on the Australian [ASX] and New Zealand [NZX] stock exchanges since December 2015 and has significant local sales operations in Australasia together with R&D activities in pain, orphan drugs and medical devices.

For more information about AFT, please visit: www.aftpharma.com

About Amicus A.G.

Amicus subsidiaries operate in the Balkan and Baltic countries of Albania, Croatia, Estonia, Kosovo, Latvia, Lithuania, Macedonia, Montenegro, Serbia, Slovenia, and now also Hungary. Set up in 2014, Amicus has gathered outstanding pharmaceutical talent, including long experience in the OTC / consumer healthcare. The company specializes in representing research-based specialty pharmaceuticals, (licensed and pre-registration products imported under special license), as well as self-care brands.

For more information about Amicus, please visit: www.amicuspharma.eu

Contact:

Maja Boskovic, Public Affairs Officer, Amicus

Maja.Boskovic@amicuspharma.eu, Tel: +381 11 4426 321